2,5-Pyridinedicarboxylic acid is a bioactive and highly selective inhibitor of D-dopachrome tautomerase.

[1]  J. Bernhagen,et al.  D‐dopachrome tautomerase in cardiovascular and inflammatory diseases—A new kid on the block or just another MIF? , 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  V. Bhandari,et al.  A Cysteine Variant at an Allosteric Site Alters MIF Dynamics and Biological Function in Homo- and Heterotrimeric Assemblies , 2022, Frontiers in Molecular Biosciences.

[3]  W. Quax,et al.  Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells , 2022, Journal of medicinal chemistry.

[4]  T. Holowka,et al.  MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model. , 2021, The Journal of clinical investigation.

[5]  Petra E. van der Wouden,et al.  4‐Iodopyrimidine Labeling Reveals Nuclear Translocation and Nuclease Activity for Both MIF and MIF2 , 2021, Chemistry.

[6]  Devin K. Schweppe,et al.  Redox-dependent Structure and Dynamics of Macrophage Migration Inhibitory Factor Reveal Sites of Latent Allostery , 2021, bioRxiv.

[7]  George P. Lisi,et al.  The N-terminus of MIF Regulates the Dynamic Profile of Residues Involved in CD74 Activation. , 2021, Biophysical journal.

[8]  V. Bhandari,et al.  A structurally preserved allosteric site in the MIF superfamily affects enzymatic activity and CD74 activation in D-dopachrome tautomerase , 2021, The Journal of biological chemistry.

[9]  John Z. H. Zhang,et al.  MolGpka: A Web Server for Small Molecule pKa Prediction Using a Graph-Convolutional Neural Network , 2021, J. Chem. Inf. Model..

[10]  Bin Liu,et al.  D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling , 2021, EBioMedicine.

[11]  George P. Lisi,et al.  Regulation of MIF Enzymatic Activity by an Allosteric Site at the Central Solvent Channel. , 2020, Cell chemical biology.

[12]  B. Eynde,et al.  Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma? , 2020, Annual Review of Cancer Biology.

[13]  J. Bernhagen,et al.  Differential regulation of macrophage activation by the MIF cytokine superfamily members MIF and MIF‐2 in adipose tissue during endotoxemia , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Avner Schlessinger,et al.  PyVOL: a PyMOL plugin for visualization, comparison, and volume calculation of drug-binding sites , 2019, bioRxiv.

[15]  L. Leng,et al.  A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity , 2019, The Journal of Biological Chemistry.

[16]  F. Vincent,et al.  Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis , 2018, Clinical & translational immunology.

[17]  L. Leng,et al.  Nanosecond Dynamics Regulate the MIF-Induced Activity of CD74. , 2018, Angewandte Chemie.

[18]  R. Bucala,et al.  Structural Plasticity in the C-Terminal Region of Macrophage Migration Inhibitory Factor-2 Is Associated with an Induced Fit Mechanism for a Selective Inhibitor. , 2018, Biochemistry.

[19]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[20]  Botao Wang,et al.  D‐dopachrome tautomerase is over‐expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth , 2016, International journal of cancer.

[21]  J. Qian,et al.  A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1 , 2016, Science.

[22]  T. Y. Cho,et al.  Structural basis for decreased induction of class IB PI3‐kinases expression by MIF inhibitors , 2016, Journal of cellular and molecular medicine.

[23]  L. Kenner,et al.  Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer , 2016, Oncotarget.

[24]  A. Schetter,et al.  A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. , 2016, Cancer research.

[25]  R. Bucala,et al.  An Analysis of MIF Structural Features that Control Functional Activation of CD74. , 2015, Chemistry & biology.

[26]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[27]  H. Tilg,et al.  Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions , 2015, The Journal of Immunology.

[28]  J. Bernhagen,et al.  MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP‐70 signaling, and lymphocyte chemotaxis , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  R. Bucala,et al.  Targeting distinct tautomerase sites of D‐DT and MIF with a single molecule for inhibition of neutrophil lung recruitment , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  L. Leng,et al.  The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. , 2014, The Journal of clinical investigation.

[31]  H. Ball,et al.  Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1 , 2014, Amino Acids.

[32]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[33]  R. Bucala,et al.  D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. , 2012, Cytokine.

[34]  O. Lesur,et al.  The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF) , 2011, Proceedings of the National Academy of Sciences.

[35]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[36]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[37]  Kirk W. Johnson,et al.  Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast , 2010, Proceedings of the National Academy of Sciences.

[38]  J. Bernhagen,et al.  A functional heteromeric MIF receptor formed by CD74 and CXCR4 , 2009, FEBS letters.

[39]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[40]  C. Metz,et al.  Macrophage CD74 contributes to MIF-induced pulmonary inflammation , 2009, Respiratory research.

[41]  L. Leng,et al.  Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions. , 2009, Biochemistry.

[42]  L. Leng,et al.  Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.

[43]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[44]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[45]  Oliver F. Lange,et al.  Generalized correlation for biomolecular dynamics , 2005, Proteins.

[46]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[47]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[48]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[49]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[50]  Elias Lolis,et al.  The Tautomerase Active Site of Macrophage Migration Inhibitory Factor Is a Potential Target for Discovery of Novel Anti-inflammatory Agents* , 2002, The Journal of Biological Chemistry.

[51]  P. Gregersen,et al.  A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis , 2002, Genes and Immunity.

[52]  S. Yamamoto,et al.  Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. , 2001, Journal of medicinal chemistry.

[53]  I. Tanaka,et al.  Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. , 1999, Biochemistry.

[54]  D. Wiley,et al.  Structure of a trimeric domain of the MHC class II‐associated chaperonin and targeting protein Ii , 1998, The EMBO journal.

[55]  I. Tanaka,et al.  Molecular cloning of human D-dopachrome tautomerase cDNA: N-terminal proline is essential for enzyme activation. , 1998, Biochemical and biophysical research communications.

[56]  J. Bernhagen,et al.  Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[58]  M. Pabst,et al.  Removal of endotoxin from protein solutions by phase separation using Triton X-114. , 1990, Journal of immunological methods.

[59]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.

[60]  P. Tilstam,et al.  Elucidating the role of an immunomodulatory protein in cancer: From protein expression to functional characterization. , 2019, Methods in enzymology.

[61]  Y. Al-Abed,et al.  MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. , 2011, Future medicinal chemistry.

[62]  M. Feldmann,et al.  Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis , 2007, Molecular medicine.

[63]  E. Norkus,et al.  Interaction of pyridine‐2,5‐dicarboxylic acid with heavy metal ions in aqueous solutions , 2005 .

[64]  R. Bucala,et al.  The Immunoregulatory Mediator Macrophage Migration Inhibitory Factor (MIF) Catalyzes a Tautomerization Reaction , 1996, Molecular medicine.